AQR Capital Management
MTNB icon

AQR Capital Management’s Matinas BioPharma MTNB Stock Holding History

AQR Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-289
Closed -$17K – 2259
2017
Q4 		$17K Hold
289
– – ﹤0.01% 2214
2017
Q3 		$19K Buy
+289
New +$19.3K ﹤0.01% 2233

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWMG
Alliance Wealth Management Group Flemington, New Jersey $457M AUM 12.13% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

AQR Capital Management's MTNB Position: Q1 2018 in Review

AQR Capital Management sold out of Matinas BioPharma (MTNB) in Q1 2018, closing a stake of 289 shares — an estimated $17K sold.

AQR Capital Management first reported a position in MTNB in Q3 2017 and held it in 2 quarters. The position peaked at $19K in Q3 2017. 45 funds tracked by Wall St. Rank hold MTNB as of Q1 2018.

  • AQR Capital Management reported no remaining Matinas BioPharma position as of Q1 2018 after selling out during the quarter.
  • AQR Capital Management sold 289 Matinas BioPharma shares in Q1 2018, an estimated $17K.
  • AQR Capital Management first reported a position in Matinas BioPharma in Q3 2017 and held it in 2 quarters.
  • AQR Capital Management's Matinas BioPharma position peaked at $19K in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2018.

Based on AQR Capital Management's 13F filing for Q1 2018, filed 15 May 2018.